These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

347 related articles for article (PubMed ID: 28777458)

  • 1. Increased expression of PD-L1 and PD-L2 in dermal fibroblasts from alopecia areata mice.
    Li Y; Kilani RT; Pakyari M; Leung G; Nabai L; Ghahary A
    J Cell Physiol; 2018 Mar; 233(3):2590-2601. PubMed ID: 28777458
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human brain endothelial cells endeavor to immunoregulate CD8 T cells via PD-1 ligand expression in multiple sclerosis.
    Pittet CL; Newcombe J; Prat A; Arbour N
    J Neuroinflammation; 2011 Nov; 8():155. PubMed ID: 22067141
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interferon-gamma-deficient mice are resistant to the development of alopecia areata.
    Freyschmidt-Paul P; McElwee KJ; Hoffmann R; Sundberg JP; Vitacolonna M; Kissling S; Zöller M
    Br J Dermatol; 2006 Sep; 155(3):515-21. PubMed ID: 16911275
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Programmed death-1 ligands 1 and 2 expression in cutaneous squamous cell carcinoma and their relationship with tumour- infiltrating dendritic cells.
    Jiao Q; Liu C; Li W; Li W; Fang F; Qian Q; Zhang X
    Clin Exp Immunol; 2017 Jun; 188(3):420-429. PubMed ID: 28052400
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Resistance to alopecia areata in C3H/HeJ mice is associated with increased expression of regulatory cytokines and a failure to recruit CD4+ and CD8+ cells.
    McElwee KJ; Hoffmann R; Freyschmidt-Paul P; Wenzel E; Kissling S; Sundberg JP; Zöller M
    J Invest Dermatol; 2002 Dec; 119(6):1426-33. PubMed ID: 12485450
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SOCS3 treatment prevents the development of alopecia areata by inhibiting CD8+ T cell-mediated autoimmune destruction.
    Gao Z; Jin YQ; Wu W
    Oncotarget; 2017 May; 8(20):33432-33443. PubMed ID: 28418931
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hantavirus-Driven PD-L1/PD-L2 Upregulation: An Imperfect Viral Immune Evasion Mechanism.
    Raftery MJ; Abdelaziz MO; Hofmann J; Schönrich G
    Front Immunol; 2018; 9():2560. PubMed ID: 30559738
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production.
    Brown JA; Dorfman DM; Ma FR; Sullivan EL; Munoz O; Wood CR; Greenfield EA; Freeman GJ
    J Immunol; 2003 Feb; 170(3):1257-66. PubMed ID: 12538684
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Programmed Cell Death 1 Ligand 1 and Programmed Cell Death 1 Ligand 2 Are Expressed in Conjunctival Invasive Squamous Cell Carcinoma: Therapeutic Implications.
    Wolkow N; Jakobiec FA; Afrogheh AH; Eagle RC; Pai SI; Faquin WC
    Am J Ophthalmol; 2019 Apr; 200():226-241. PubMed ID: 30633894
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hormonal vitamin D up-regulates tissue-specific PD-L1 and PD-L2 surface glycoprotein expression in humans but not mice.
    Dimitrov V; Bouttier M; Boukhaled G; Salehi-Tabar R; Avramescu RG; Memari B; Hasaj B; Lukacs GL; Krawczyk CM; White JH
    J Biol Chem; 2017 Dec; 292(50):20657-20668. PubMed ID: 29061851
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential role of programmed death-ligand 1 [corrected] and programmed death-ligand 2 [corrected] in regulating the susceptibility and chronic progression of experimental autoimmune encephalomyelitis.
    Zhu B; Guleria I; Khosroshahi A; Chitnis T; Imitola J; Azuma M; Yagita H; Sayegh MH; Khoury SJ
    J Immunol; 2006 Mar; 176(6):3480-9. PubMed ID: 16517716
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reactive glia promote development of CD103
    Prasad S; Hu S; Sheng WS; Chauhan P; Lokensgard JR
    Immun Inflamm Dis; 2018 Jun; 6(2):332-344. PubMed ID: 29602245
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TLR9 Mediated Tumor-Stroma Interactions in Human Papilloma Virus (HPV)-Positive Head and Neck Squamous Cell Carcinoma Up-Regulate PD-L1 and PD-L2.
    Baruah P; Bullenkamp J; Wilson POG; Lee M; Kaski JC; Dumitriu IE
    Front Immunol; 2019; 10():1644. PubMed ID: 31379843
    [No Abstract]   [Full Text] [Related]  

  • 14. Nafamostat mesilate, a serine protease inhibitor, suppresses interferon-gamma-induced up-regulation of programmed cell death ligand 1 in human cancer cells.
    Homma S; Hayashi K; Yoshida K; Sagawa Y; Kamata Y; Ito M
    Int Immunopharmacol; 2018 Jan; 54():39-45. PubMed ID: 29100036
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of PI3Kδ Differentially Regulates Poly I:C- and Human Metapneumovirus-Induced PD-L1 and PD-L2 Expression in Human Bronchial Epithelial Cells.
    Ogawa T; Kan-O K; Shiota A; Fujita A; Ishii Y; Fukuyama S; Matsumoto K
    Front Immunol; 2021; 12():767666. PubMed ID: 34899719
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Programmed death 1 ligand (PD-L) 1 and PD-L2 limit autoimmune kidney disease: distinct roles.
    Menke J; Lucas JA; Zeller GC; Keir ME; Huang XR; Tsuboi N; Mayadas TN; Lan HY; Sharpe AH; Kelley VR
    J Immunol; 2007 Dec; 179(11):7466-77. PubMed ID: 18025191
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential Involvement of Programmed Cell Death Ligands in Skin Immune Responses.
    Tanaka R; Ichimura Y; Kubota N; Saito A; Nakamura Y; Ishitsuka Y; Watanabe R; Fujisawa Y; Mizuno S; Takahashi S; Fujimoto M; Okiyama N
    J Invest Dermatol; 2022 Jan; 142(1):145-154.e8. PubMed ID: 34310947
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The IFN-γ/PD-L1 axis between T cells and tumor microenvironment: hints for glioma anti-PD-1/PD-L1 therapy.
    Qian J; Wang C; Wang B; Yang J; Wang Y; Luo F; Xu J; Zhao C; Liu R; Chu Y
    J Neuroinflammation; 2018 Oct; 15(1):290. PubMed ID: 30333036
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Substance P as an immunomodulatory neuropeptide in a mouse model for autoimmune hair loss (alopecia areata).
    Siebenhaar F; Sharov AA; Peters EM; Sharova TY; Syska W; Mardaryev AN; Freyschmidt-Paul P; Sundberg JP; Maurer M; Botchkarev VA
    J Invest Dermatol; 2007 Jun; 127(6):1489-97. PubMed ID: 17273166
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tissue expression of PD-L1 mediates peripheral T cell tolerance.
    Keir ME; Liang SC; Guleria I; Latchman YE; Qipo A; Albacker LA; Koulmanda M; Freeman GJ; Sayegh MH; Sharpe AH
    J Exp Med; 2006 Apr; 203(4):883-95. PubMed ID: 16606670
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.